WO2000075157A1 - Oligonucleotide synthesis with lewis acids as activators - Google Patents
Oligonucleotide synthesis with lewis acids as activators Download PDFInfo
- Publication number
- WO2000075157A1 WO2000075157A1 PCT/US2000/012530 US0012530W WO0075157A1 WO 2000075157 A1 WO2000075157 A1 WO 2000075157A1 US 0012530 W US0012530 W US 0012530W WO 0075157 A1 WO0075157 A1 WO 0075157A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- chloride
- composition according
- alkoxy
- magnesium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- the present invention relates to a process utilizing Lewis acids as activators in the preparation of oligonucleotides by phosphoramidite chemistry.
- the present invention relates generally to the fields of organic chemistry and biology.
- the present invention is directed to compositions and methods for use in oligonucleotide synthesis.
- Phosphoramidite chemistry (Beaucage, S. L., and Lyer, R. P. Tetrahedron (1992), 48, 2223-2311) has become by far the most widely used coupling chemistry for the synthesis of oligonucleotides.
- phosphoramidite synthesis of oligonucleotides involves activation of nucleoside phosphoramidite monomer precursors by reaction with an activating agent to form activated intermediates, followed by sequential addition of the activated intermediates to the growing oligonucleotide chain (generally anchored at one end to a suitable solid support) to form the oligonucleotide product.
- Tetrazole is commonly used for the activation of the nucleoside phosphoramidite monomers; the activation occurs by the mechanism depicted in Scheme I.
- Tetrazole has an acidic proton which presumably protonates the basic nitrogen of the diisopropylamino phosphine group, thus making the diisopropylamino group a leaving group.
- the negatively charged tetrazolium ion then makes an attack on the trivalent phosphorous, forming a transient phosphorous tetrazolide species.
- the 5'-OH group of the solid support bound nucleoside then attacks the active trivalent phosphorous species, resulting in the formation of the internucleotide linkage.
- tetrazole Principal drawbacks of tetrazole are its cost and instability which includes its potential to explode (Material Safety Data Sheets or MSDS lists IH-tetrazole as a severe explosion hazard). Because of its inherent instability, sublimed tetrazole is generally required to ensure desired coupling yields. Further, tetrazole (which is typically used near its saturated solubility of 0.5M) tends to precipitate out of acetonitrile solution at cold temperatures; this can lead to valve blockage on some automated DNA synthesizers. Other activators which work almost as efficiently as tetrazole have similar drawbacks to those of tetrazole as discussed above.
- activators which are all proton donors, include the following members of the tetrazole class of activators: 5-(p- nitrophenyl) tetrazole (Froehler, B. C. and Mattcucci, M. D., Tetrahedron Letters (1983), 24, 3171-3174); 5-(p-nitrophenyl) tetrazole and DMAP (Pon, R.T., Tetrahedron Letters (1987), 28, 3643-3646); and 5-(ethylthio)- IH-tetrazole (Wright, P. et al., Tetrahedron
- a 1 :1 mixture of benzimidazole and BF 3 etherate is disclosed wherein the BF 3 component acts to increase the acidity of the benzimidazole proton necessary for activation of the phosphoramidite (intermediates).
- the benzimidazole BF 3 complex acts in a manner similar to tetrazole described in Scheme 1.
- the present invention does not activate phosphoramidite intermediates with a proton donor but instead utilizes Lewis acids for activation.
- BF 3 etherate is used in the present invention.
- the advantages of BF 3 etherate over the benzimidazole BF 3 complex include commercial availability and ease of removal of diethyl ether versus removal of benzimidazole.
- the activated phosphoramidite intermediates are highly sensitive to moisture. An excess of 50% to 100% of the highly valuable phosphoramidites are required for sequencing even with anhydrous solvents ( ⁇ 20 ppm moisture content). The presence of trace amounts of moisture results in considerable loss of yield and an increase in deleted sequencing impurities.
- Lewis acids can act as moisture scavengers minimizing decomposition of the phosphoramidite. Therefore, the use of Lewis acids for activation of phosphoramidite intermediates leads to improved coupling efficiency, lower cost, and convenient material handling and operation.
- B 1 is selected from the group consisting of a purine base and a pyrimidine base;
- R 1 is a secondary amine, a preferred amine is diisopropylamine;
- R 2 is selected from the group consisting of alkoxy, alkyl, alkylsulfonylalkoxy arylsulfonylalkoxy, cyanoalkoxy, and haloalkoxy;
- R 3 is a hydroxy-protecting group, a preferred group is 4-4'-dimethoxytrityl
- R 4 is selected from the group consisting of hydrogen and -OR 7 wherein, R 7 is a hydroxy- protecting group; comprising treating the phosphoramidite monomers of formula I with an optional amount of pyridine and a Lewis acid, preferred Lewis acids are selected from aluminum chloride, bismuth(III) chloride, boron trifluoride, iron(II) chloride, iron(III) chloride, magnesium bromide, magnesium chloride, magnesium trifluoromethanesulfonate, manganese(II) chloride, zinc bromide, zinc chloride and zirconium(IN) chloride.
- preferred Lewis acids are selected from aluminum chloride, bismuth(III) chloride, boron trifluoride, iron(II) chloride, iron(III) chloride, magnesium bromide, magnesium chloride, magnesium trifluoromethanesulfonate, manganese(II) chloride, zinc bromide, zinc chloride and zirconium(IN) chloride.
- alkoxy refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and the like.
- alkyl refers to a straight or branched chain hydrocarbon containing from 1 to 5 carbon atoms.
- Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, and the like.
- alkylcarbonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of alkylcarbonyl include, but are not limited to, acetyl, ethylcarbonyl, and the like.
- alkylcarbonyloxy refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, t-butylcarbonyloxy, and the like.
- alkylsulfonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl, ethylsulfonyl, and the like.
- alkylsulfonylalkoxy refers to an alkylsulfonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- Representative examples of alkylsulfonylalkoxy include, but are not limited to, 2-methylsulfonylethoxy, 2-ethylsulfonylethoxy, and the like.
- amino refers to a -NH 2 group.
- amino-protecting group or “N-protecting group,” refer to groups intended to protect an amino group against undersirable reactions during synthetic procedures. Commonly used nitrogen-protecting groups are disclosed in Greene, T. W., &
- nitrogen-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).
- aryl refers to an aromatic monocyclic ring system, or a bicyclic-fused ring system wherein one or both of the fused rings are aromatic.
- aryl include, but are not limited to, azulene, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.
- the aryl groups of this invention can be substituted with 1, 2, or 3 substituents independently selected from alkyl, cyano, halogen, haloalkyl, and nitro.
- arylalkoxy refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- arylalkoxy include, but are not limited to, 2-phenylethoxy, 2-naphthylethoxy, 2-(4-nitrophenyl)ethoxy, and the like.
- arylsulfonyl refers to an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- arylsulfonyl include, but are not limited to, phenylsulfonyl, naphthylsulfonyl, and the like.
- arylsulfonylalkoxy refers to an arylsulfonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- Representative examples of arylsulfonylalkoxy include, but are not limited to, 2-phenylsulfonylethoxy, 3-phenylsulfonylpropoxy, and the like.
- carbonyl refers to a -C(O)- group.
- catechol refers to a C 6 H 4 - 1 ,2-(O-) 2 group, wherein both oxygen atoms are attached to M, as defined herein.
- cyano refers to a -CN group.
- cyanoalkoxy refers to a cyano group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- Representative examples of cyanoalkoxy include, but are not limited to, 2-cyanoethoxy, 3-cyanopropoxy, 1 -methyl-2-cyanoethoxy, l,l-dimethyl-2-cyanoethoxy, and the like.
- halo refers to -Cl, -Br, -I or -F.
- haloalkoxy refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, 2,2,2- trichloroethoxy, l,l-dimethyl-2,2,2-trichloroethoxy, trifluoromethoxy, and the like.
- haloalkyl refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifiuoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and the like.
- hydroxy-protecting group or "O-protecting group” refers to groups intended to protect a hydroxy group against undesirable reactions during synthetic procedures. Commonly used hydroxy-protecting groups are disclosed in T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis. 2nd edition, John Wiley & Sons, New York (1991), which is hereby incorporated by reference.
- hydroxy- protecting groups include, but are not limited to, substituted methyl ethers, for example, methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)- ethoxymethyl, benzyl, and triphenylmethyl; tetrahydropyranyl ethers; substituted ethyl ethers, for example, 2,2,2-trichloroethyl and t-butyl; silyl ethers, for example, trimethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl; cyclic acetals and ketals, for example, methylene acetal, acetonide and benzylidene acetal; cyclic ortho esters, for example, methoxymethylene; cyclic carbonates; cyclic boronates; carbonyl derivatives, for example, acetyl, p-phenylazopheny
- Lewis acid refers to a chemical species, other than a proton, that has a vacant orbital or accepts an electron pair. It is to be understood that Lewis acids can be purchased or prepared as complexes including but not limited to, etherates, hydrates, and thioetherates. It is to be further understood that complexes purchased or prepared for the present invention do not contain an acidic proton.
- Lewis acid examples include, but are not limited to, aluminum chloride, bismuth(III) chloride, boron trifluoride, iron(II) chloride, iron(III) chloride, magnesium bromide, magnesium chloride, magnesium trifluoromethanesulfonate, manganese(II) chloride, zinc bromide, zinc chloride, zirconium(IV) chloride, and the like.
- methylenedioxy refers to a -OC(R 80 )(R 81 )O- group wherein R 80 and R 81 are independently selected from hydrogen and alkyl. The oxygen atoms of the methylenedioxy group are attached to the parent molecular moiety through two adjacent carbon atoms.
- methylenedioxy group examples include, but are not limited to, 1,3-dioxolanyl, 2,2-dimethyl-l,3-dioxolanyl, 2-methyl-l,3- dioxolanyl, and the like.
- purine base refers to an organic base selected from 9H-purin-6-ylamine (adenine) and 2-amino-l,9-dihydro-6H-purin-6-one (guanine).
- adenine 9H-purin-6-ylamine
- guanine 2-amino-l,9-dihydro-6H-purin-6-one
- the amino group attached to adenine can be protected with a nitrogen-protecting group.
- proto refers to H + .
- pyrimidine base refers to an organic base selected from 2,4(lH,3H)-pyrimidinedione (uracil), 5-methyl-2,4(lH,3H)-pyrimidinedione (thymine), and 4-amino-2(lH)-pyrimidinone (cytosine).
- uracil 2,4(lH,3H)-pyrimidinedione
- thymine 5-methyl-2,4(lH,3H)-pyrimidinedione
- cytosine 4-amino-2(lH)-pyrimidinone
- the amino group attached to cytosine can be protected with a nitrogen-protecting group.
- sulfonyl refers to a -SO 2 - group.
- trifluoromethane refers to a -CF 3 group.
- trifluoromethanesulfonyl refers to a trifluoromethane group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- trifluoromethanesulfonyloxy refers to a trifluoromethanesulfonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- dimer (iii) can be oxidizied using standard conditions know to those of ordinary skill in the art to give the phosphate, (J. Am. Chem. Soc, (1976), 98, 3655-3661).
- the 5'-OH of the oxidized dimer can be deprotected and treated with a Lewis acid activated phophoramidite monomer to form a trimer. This sequence of steps can be repeated until an oligonucleotide of desired length has been synthesized such that the process of the present invention can be used for preparing oligonucleotides, including solid phase synthesis thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00926516A EP1181301A1 (en) | 1999-06-03 | 2000-05-08 | Oligonucleotide synthesis with lewis acids as activators |
JP2001502438A JP2003514766A (en) | 1999-06-03 | 2000-05-08 | Oligonucleotide synthesis using Lewis acids as activators |
MXPA01012444A MXPA01012444A (en) | 1999-06-03 | 2000-05-08 | Oligonucleotide synthesis with lewis acids as activators. |
CA002376016A CA2376016A1 (en) | 1999-06-03 | 2000-05-08 | Oligonucleotide synthesis with lewis acids as activators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32505599A | 1999-06-03 | 1999-06-03 | |
US09/325,055 | 1999-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000075157A1 true WO2000075157A1 (en) | 2000-12-14 |
Family
ID=23266253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012530 WO2000075157A1 (en) | 1999-06-03 | 2000-05-08 | Oligonucleotide synthesis with lewis acids as activators |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1181301A1 (en) |
JP (1) | JP2003514766A (en) |
CA (1) | CA2376016A1 (en) |
MX (1) | MXPA01012444A (en) |
WO (1) | WO2000075157A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107074902A (en) * | 2014-10-29 | 2017-08-18 | 吉利德科学公司 | The method for preparing ribonucleotide |
US10988498B2 (en) | 2009-09-21 | 2021-04-27 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs |
US11007208B2 (en) | 2015-09-16 | 2021-05-18 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
US11260070B2 (en) | 2017-03-14 | 2022-03-01 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
US11266681B2 (en) | 2017-07-11 | 2022-03-08 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
US11492353B2 (en) | 2010-07-22 | 2022-11-08 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
US11491169B2 (en) | 2020-05-29 | 2022-11-08 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
US11701372B2 (en) | 2020-04-06 | 2023-07-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs |
US11780844B2 (en) | 2022-03-02 | 2023-10-10 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11814406B2 (en) | 2020-08-27 | 2023-11-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
US12030906B2 (en) | 2023-01-20 | 2024-07-09 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5283178B2 (en) * | 2009-03-05 | 2013-09-04 | 株式会社島津製作所 | Matrix for matrix-assisted laser desorption / ionization mass spectrometry |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08301878A (en) * | 1995-04-28 | 1996-11-19 | Toagosei Co Ltd | Synthesis of boron trifluoride coordinated compound and oligonucleotide |
-
2000
- 2000-05-08 WO PCT/US2000/012530 patent/WO2000075157A1/en not_active Application Discontinuation
- 2000-05-08 MX MXPA01012444A patent/MXPA01012444A/en unknown
- 2000-05-08 CA CA002376016A patent/CA2376016A1/en not_active Abandoned
- 2000-05-08 EP EP00926516A patent/EP1181301A1/en not_active Withdrawn
- 2000-05-08 JP JP2001502438A patent/JP2003514766A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08301878A (en) * | 1995-04-28 | 1996-11-19 | Toagosei Co Ltd | Synthesis of boron trifluoride coordinated compound and oligonucleotide |
Non-Patent Citations (1)
Title |
---|
BEAUCAGE S L ET AL: "ADVANCES IN THE SYNTHESIS OF OLIGONUCLEOTIDES BY THE PHOSPHORAMIDITE APPROACH", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 48, no. 12, 1992, pages 2223 - 2311, XP000915225, ISSN: 0040-4020 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10988498B2 (en) | 2009-09-21 | 2021-04-27 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs |
US11492353B2 (en) | 2010-07-22 | 2022-11-08 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
CN107074902A (en) * | 2014-10-29 | 2017-08-18 | 吉利德科学公司 | The method for preparing ribonucleotide |
CN113549120A (en) * | 2014-10-29 | 2021-10-26 | 吉利德科学公司 | Process for preparing ribonucleosides |
US11266666B2 (en) | 2014-10-29 | 2022-03-08 | Gilead Sciences, Inc. | Methods for treating Filoviridae virus infections |
US11344565B2 (en) | 2014-10-29 | 2022-05-31 | Gilead Sciences, Inc. | Methods for the preparation of ribosides |
US11007208B2 (en) | 2015-09-16 | 2021-05-18 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
US11382926B2 (en) | 2015-09-16 | 2022-07-12 | Gilead Sciences, Inc. | Methods for treating Arenaviridae and Coronaviridae virus infections |
US11260070B2 (en) | 2017-03-14 | 2022-03-01 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
US11266681B2 (en) | 2017-07-11 | 2022-03-08 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
US11975017B2 (en) | 2017-07-11 | 2024-05-07 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
US12012431B2 (en) | 2020-03-12 | 2024-06-18 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
US11701372B2 (en) | 2020-04-06 | 2023-07-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs |
US11975012B2 (en) | 2020-05-29 | 2024-05-07 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11903953B2 (en) | 2020-05-29 | 2024-02-20 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11491169B2 (en) | 2020-05-29 | 2022-11-08 | Gilead Sciences, Inc. | Remdesivir treatment methods |
US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11814406B2 (en) | 2020-08-27 | 2023-11-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11845755B2 (en) | 2022-03-02 | 2023-12-19 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11851438B2 (en) | 2022-03-02 | 2023-12-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and methods for treatment of viral infections |
US11780844B2 (en) | 2022-03-02 | 2023-10-10 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US12030906B2 (en) | 2023-01-20 | 2024-07-09 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate |
Also Published As
Publication number | Publication date |
---|---|
EP1181301A1 (en) | 2002-02-27 |
MXPA01012444A (en) | 2002-07-30 |
JP2003514766A (en) | 2003-04-22 |
CA2376016A1 (en) | 2000-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5763599A (en) | Nucleoside derivatives with photolabile protective groups | |
JP4402454B2 (en) | Method for producing LNA phosphoramidite | |
AU651289B2 (en) | Process of linking nucleosides with a siloxane bridge | |
EP0577303B1 (en) | Stereoselective glycosylation process | |
EP1181301A1 (en) | Oligonucleotide synthesis with lewis acids as activators | |
IL106266A (en) | Process for the preparation of 2(-o-alkyl guanosine and related compounds | |
EP1874792A1 (en) | Activators for oligonucleotide and phosphoramidite synthesis | |
AU711814B2 (en) | Nucleoside derivatives with photolabile protective groups | |
US5459243A (en) | Apparatus and processes for the large scale generation and transfer of diazomethane | |
EP1317466B1 (en) | Synthons for oligonucleotide synthesis | |
US5606049A (en) | Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis | |
US4419509A (en) | Process for de-cyanoethylating blocked nucleotides | |
EP3844167A1 (en) | Method for preparing 3'-o-amino-2'-deoxyribonucleoside-5'-triphosphate | |
JP4709959B2 (en) | Nucleoside phosphoramidite compounds | |
Efimov et al. | N-azidomethylbenzoyl blocking group in the phosphotriester synthesis of oligoribonucleotides | |
US20020146737A1 (en) | Nucleoside derivatives with photolabile protective groups | |
US5631362A (en) | 5'-O-Dans EOC modified nucleosides and methods for preparing same | |
Pannecouque et al. | Synthesis, enzymatic stability and physicochemical properties of oligonucleotides containing a N-cyanoguanidine linkage. | |
RU2131880C1 (en) | Method of preparing beta-anomer enriched nucleosides | |
CA2362714A1 (en) | 2'-substituted rna preparation | |
PL221806B1 (en) | Method for introduction of acetal and acetal-ester protecting group and its use to protect a hydroxyl function | |
JPH0376319B2 (en) | ||
EP0075392A1 (en) | Process for de-cyanoethylating blocked nucleotides | |
JPH01308296A (en) | Method for removing anilino or derivative residue thereof from phosphoroanilidates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2376016 Country of ref document: CA Ref country code: CA Ref document number: 2376016 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 2001 502438 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/012444 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000926516 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000926516 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000926516 Country of ref document: EP |